BRIDGEWATER, NJ - Tharimmune, Inc. (NASDAQ:THAR), a biotech firm engaged in inflammation and immunology therapies, announced today the establishment of a Scientific Advisory Board (SAB). The SAB is composed of experts in immunology, liver diseases, and antibody drug conjugates, aiming to steer the development of the company's therapeutic candidates.
The SAB's expertise will be instrumental in advancing Tharimmune's lead clinical-stage asset, TH104, which targets chronic pruritis associated with primary biliary cholangitis (PBC). This condition is characterized by severe itching and currently lacks effective treatments. TH104 is designed to bypass first-pass metabolism, a common limitation of traditional oral formulations. The company anticipates launching a Phase 2 study in 2024.
The SAB includes renowned figures such as Andreas Kremer, MD, PhD, a specialist in autoimmune and cholestatic liver diseases, and Alan Bonder, MD, AGAF, an expert in liver diseases and liver transplant at Beth Israel Deaconess Medical Center. Their clinical experience is expected to help guide Tharimmune's research and development efforts.
In addition to TH104, Tharimmune is exploring novel antibodies derived from bovine animals. These antibodies feature ultra-long complementary determining regions which may enable them to access previously inaccessible epitopes. The smaller size and structural diversity of these Knob domains could potentially allow for multi-specific targeting of cell surface portions, offering a new approach to treating various diseases.
The advisory group also includes John Lambert, PhD, a pioneer in antibody-drug conjugate technology, and Vaughn Smider, MD, PhD, known for his work in antibody molecular biology. Their contributions are anticipated to support the development of next-generation antibody and ADC platforms.
Tharimmune highlighted its financial stability, with funding projected to sustain operations into early 2025, allowing for a phase 2 clinical readout of TH104. The company plans to provide an R&D update in 2024.
The information in this article is based on a press release statement.
InvestingPro Insights
As Tharimmune, Inc. (NASDAQ:THAR) continues to advance its clinical-stage asset, TH104, and establish its Scientific Advisory Board, a closer look at the company's financial health and stock performance is essential for investors. According to InvestingPro data, Tharimmune holds a market capitalization of $4.53 million. Despite the challenges faced by the biotech sector, Tharimmune's financial strategy seems prudent, with the company maintaining more cash than debt on its balance sheet, which is reassuring for investors considering the long-term nature of biotech investments.
InvestingPro Tips suggest that Tharimmune's stock price has experienced significant volatility, which is not uncommon in the biotech industry. This volatility is reflected in the stock's one-year total return, which has seen a dramatic decrease of 98.37%. However, it's worth noting that there has been a strong return over the last month of 23.83%, which could indicate investor optimism in the short term. The company’s liquid assets also exceed its short-term obligations, providing some financial flexibility as it continues its research and development activities.
Tharimmune does not pay a dividend, which is typical for companies in the growth phase, especially within biotech where reinvestment is crucial for product development. As Tharimmune approaches its next earnings date on May 7, 2024, investors will likely be looking for updates on the progress of TH104 and the company's overall R&D trajectory. For those interested in a deeper analysis, InvestingPro offers additional insights, including PRONEWS24 to get an extra 10% off a yearly or biyearly Pro and Pro+ subscription, providing a comprehensive suite of tools for informed investment decisions. There are 10 additional InvestingPro Tips available for Tharimmune, which can further guide investors in understanding the company's potential and risks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.